Johnson & Johnson (JNJ) Price & Analysis

Compare

147 Followers

JNJ Stock Chart & Stats

€174.98

-€0.18(-0.13%)

At close: Jan 09 4:00 PM EST

€174.98

-€0.18(-0.13%)

Day’s Range― - ―

52-Week Range€128.16 - €183.96

Previous CloseN/A

Volume223.00

Average Volume (3M)4.03K

Market Cap

$425.16B

Enterprise Value€429.24B

Total Cash (Recent Filing)$18.56B

Total Debt (Recent Filing)$45.80B

Price to Earnings (P/E)18.5

Beta0.19

Next Earnings

Jan 21, 2026

EPS Estimate

2.16

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)2.39

Shares Outstanding2,409,295,200

10 Day Avg. Volume4,248

30 Day Avg. Volume4,027

Financial Highlights & Ratios

PEG Ratio-0.42

Price to Book (P/B)4.83

Price to Sales (P/S)3.88

P/FCF Ratio17.39

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue4.66

Enterprise Value/Gross Profit6.84

Enterprise Value/Ebitda10.85

Forecast

1Y Price Target

$183.88

Price Target Upside5.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Corporate StrategyJNJ announced a planned separation of its ortho business, which should boost the company's outer year growth.

Pharmaceutical AdvancementsTecvayli + Darzalex demonstrated significantly improved progression-free survival and overall response rates in the MajesTEC-3 trial, indicating strong efficacy in the treatment setting.

Stock PerformanceJNJ shares have continued their impressive performance, with the stock up approximately 30% since July 1.

Bears Say

Pipeline ChallengesOpportunities for further re-rate are constrained by limited pipeline catalysts and lack of conviction on upward estimate revisions.

Tax ImplicationsJNJ now expects a higher tax rate of 17.5%-18.0% due to the OBBBA.

Valuation ConcernsThe stock is rated as Neutral with about-average growth and an above-average valuation, implying JNJ is fairly valued.

Johnson & Johnson News

3 Best ETFs to Invest In, According to AI Analyst, 12/23/2025

With thousands of ETFs competing for attention, spotting the real winners can be challenging. TipRanks’ ETF AI Analyst...

4d ago

JNJ

MGC

Morning Movers: Novo Nordisk gains after Wegovy pill approved

Stock futures edged lower after delayed economic data arrived far stronger than expected. The U.S. economy posted robust...

4d ago

HII

JNJ

Jury orders Johnson & Johnson to pay over $1.5B in talc case, Reuters says

A Baltimore jury has ordered Johnson & Johnson (JNJ) and its subsidiaries to pay more than $1.5B to...

5d ago

JNJ

KVUE

Johnson & Johnson issues statement on Craft verdict, intends to appeal

Erik Haas, worldwide VP of litigation, Johnson & Johnson said: “We will immediately appeal this egregious and patently...

5d ago

JNJ

Johnson & Johnson (JNJ) Faces $1.56 Billion Blow in Asbestos Lawsuit

A Maryland jury ordered Johnson & Johnson ($JNJ) to pay about $1.56 billion to a woman who claimed...

5d ago

JNJ

KVUE

Government deals lift overhang on pharma group, says BofA

BofA says Friday’s U.S. Government deals with big pharmaceutical companies were generally in-line with prior updates and provide...

6d ago

AZN

BMY

Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports

At least seven drugmakers, including GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY), are expected to announce price cuts...

8d ago

AZN

BMY

Johnson & Johnson announces FDA approval of TRUFILL n-BCA Liquid Embolic System

Johnson & Johnson MedTech announced that the U.S. FDA has approved an expanded indication for the TRUFILL n-BCA...

10d ago

JNJ

Johnson & Johnson price target raised to $240 from $213 at Goldman Sachs

Goldman Sachs analyst Asad Haider raised the firm’s price target on Johnson & Johnson to $240 from $213...

10d ago

JNJ

Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA

Johnson & Johnson (JNJ) has received approval from the FDA for Rybrevant Faspro – amivantamab and hyaluronidase-lpuj -,...

10d ago

JNJ

HALO

Johnson & Johnson announces FDA approved Rybrevant in NSCLC patients

Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously...

10d ago

JNJ

3 Best ETFs to Invest In, According to AI Analyst, 12/17/2025

With thousands of ETFs to choose from, finding the right place to start isn’t easy. TipRanks’ ETF AI...

10d ago

IYH

JNJ

Johnson & Johnson price target raised to $240 from $230 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $240 from $230 and keeps an...

11d ago

JNJ

Johnson & Johnson Rival Medline Pulls Off $6B IPO, Topping 2025 Deal Table

Medical supply firm Medline Industries, a rival to pharma giant Johnson & Johnson ($JNJ), on Tuesday raised $6.3...

11d ago

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was €128.16 and its highest was €183.96 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $425.16B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Jan 21, 2026 which is in 24 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Oct 14, 2025. The company reported €2.389 earnings per share for the quarter, beating the consensus estimate of €2.353 by €0.037.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of €1.124 which represents an annual dividend yield of 2.54%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.16.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,295,200 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of €2.389 in its last earnings report, beating expectations of €2.353. Following the earnings report the stock price went down -1.774%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in DE:JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Fundamentals

Return on Equity

33.62%

Trailing 12-Months

Asset Growth

8.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Johnson & Johnson demonstrated strong overall performance with significant growth across key segments and successful new product launches. Despite challenges from STELARA's loss of exclusivity and increased tax rates, the company's strategic focus and operational achievements suggest a positive outlook.View all DE:JNJ earnings summaries

JNJ Sales Breakdown

64.13% Innovative Medicine

35.87% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

€183.88

▲(5.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"130":"€130","167":"€167","204":"€204","148.5":"€148.5","185.5":"€185.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":203.6087952,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€203.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183.884193165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€183.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":161.1902962,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€161.19</span>\n  </div></div>","useHTML":true}}],"tickPositions":[130,148.5,167,185.5,204],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.64,179.63759963076922,181.63519926153845,183.63279889230768,185.6303985230769,187.62799815384614,189.62559778461537,191.62319741538462,193.62079704615385,195.61839667692308,197.6159963076923,199.61359593846154,201.61119556923077,{"y":203.6087952,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.64,178.12032255115383,178.60064510230768,179.08096765346153,179.56129020461537,180.04161275576922,180.52193530692307,181.00225785807692,181.48258040923076,181.9629029603846,182.44322551153846,182.9235480626923,183.40387061384615,{"y":183.884193165,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.64,176.37463816923076,175.10927633846154,173.8439145076923,172.57855267692307,171.31319084615384,170.04782901538462,168.78246718461537,167.51710535384615,166.25174352307693,164.9863816923077,163.72101986153845,162.45565803076923,{"y":161.1902962,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":143.142,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.816,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.997,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.678,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.017,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.468,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.873,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.511,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.652,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.185,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.227,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.288,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >